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New Hope for Retinoblastoma Patients
Khalil Ghasemi Falavarjani, MD; Masood Naseripour, MD
Eye Research Center, Iran University of Medical Sciences, Tehran, Iran
Systemic chemotherapy regimens and focal 
treatment modalities such as radioactive 
plaque therapy have dramatically improved the 
outcomes of treatment for retinoblastoma such 
that patient survival with modern monitoring 
and treatment now exceeds 95%. Although the 
vast majority of patients respond adequately to 
current therapeutic strategies, treatment for a 
subset of patients with advanced retinoblastoma 
remains challenging. Consider an infant with 
advanced bilateral retinoblastoma, group D 
international classification (diffuse vitreous and 
subretinal seedings of the tumor) in one eye 
and group E (anterior segment invasion of the 
tumor) in the fellow eye; treatment options for 
such a patient are limited to repetitive courses 
of systemic and periocular chemotherapy, 
and/or external beam radiation therapy. These 
modalities are usually associated with significant 
adverse effects, including bone marrow 
suppression, hearing loss, systemic infections 
and increased risk of secondary cancers. In 
another small group of patients, intraocular 
tumors may regrow despite aggressive local 
and systemic treatment and no other choice 
remains but enucleation.
In a novel approach, Abramson et al 
presented their initial experience with 
superselective ophthalmic artery delivery of 
chemotherapy (chemosurgery) for children with 
advanced retinoblastoma in eyes scheduled for 
enucleation. They cannulated the ophthalmic 
artery via a femoral artery approach using 
microcatheters while the children were under 
general anesthesia and receiving anticoagulation. 
A balloon in the catheter was inflated, occluding 
the carotid artery and a chemotherapeutic 
agent (melphalan) was infused proximal to the 
occlusion. After treatment, dramatic regression 
of tumors, vitreous seeds and subretinal seeds 
were seen in all eyes while no major systemic 
or local side effect occurred. Among the 9 cases 
treated with this technique, 7 eyes (77.7%) 
destined to be enucleated were salvaged. 
Using electroretinography, the investigators 
showed that retinal function may persist and 
even recover following this technique. In a 
complementary article, they reported 4 patients 
with advanced bilateral disease (groups C-E) 
in whom initial management was bilateral 
superselective ophthalmic artery chemotherapy 
performed during the same session. All tumors 
and vitreous seeds in all subjects showed 
significant reduction in size within 3 weeks 
of treatment and no eye required radiation or 
enucleation.
Direct infusion of chemotherapeutic 
agents into the ophthalmic artery seems to 
be effective and safe both for the patient and 
the eye. Since chemosurgery does not require 
ports, transfusions, hospitalizations, and does 
not incur neutropenia or infections, the cost of 
therapy is much reduced. A cost analysis of 
intraarterial chemosurgery has estimated the 
cost of this method to be approximately half 
that of systemic chemotherapy. These promising 
initial results suggest that this approach may 
pave the way for treatment of advanced 
intraocular retinoblastoma while avoiding 
the use of multiagent systemic chemotherapy, 
enucleation, and/or radiation.
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Errata
In the January issue of this journal [J Ophthalmic Vis Res 2010; 5(1)], two errors were found 
regarding author names:
In the Photo Essay, “Bilateral Orbital Cavernous Hemangiomas” on page 65 (J Ophthalmic Vis 
Res 2010; 5(1): 65-67), the author Reza Erfanian-Salim was misspelled as Mohammad-Reza 
Erfanian. The correct authors should read:
Maryam Aletaha, MD; Reza Erfanian-Salim, MD; Abbas Bagheri, MD 
Hossein Salour, MD; Mohammad Abrishami, MD
In the Original Article, “Higher-Order Aberrations in Myopic Eyes” on page 3 (J Ophthalmic Vis 
Res 2010; 5(1): 3-9), the author Azade Doozande was omitted. The correct authors should read:
Farid Karimian, MD; Sepehr Feizi, MD; Azade Doozande, MD